Targeting Mycobacterium tuberculosis and Other Microbial Pathogens Using Improved Synthetic Antibacterial Peptides

ABSTRACT The lack of effective therapies for treating tuberculosis (TB) is a global health problem. While Mycobacterium tuberculosis is notoriously resistant to most available antibiotics, we identified synthetic short cationic antimicrobial peptides that were active at low micromolar concentrations (less than 10 μM). These small peptides (averaging 10 amino acids) had remarkably broad spectra of antimicrobial activities against both bacterial and fungal pathogens and an indication of low cytotoxicity. In addition, their antimicrobial activities displayed various degrees of species specificity that were not related to taxonomy. For example, Candida albicans and Staphylococcus aureus were the best surrogates to predict peptide activity against M. tuberculosis, while Mycobacterium smegmatis was a poor surrogate. Principle component analysis of activity spectrum profiles identified unique features associated with activity against M. tuberculosis that reflect their distinctive amino acid composition; active peptides were more hydrophobic and cationic, reflecting increased tryptophan with compensating decreases in valine and other uncharged amino acids and increased lysine. These studies provide foundations for development of cationic antimicrobial peptides as potential new therapeutic agents for TB treatment.

[1]  Noriaki Iwase,et al.  Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. , 2012, ACS chemical biology.

[2]  W. Shafer,et al.  Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Kai Hilpert,et al.  Sequence requirements and an optimization strategy for short antimicrobial peptides. , 2006, Chemistry & biology.

[4]  W. Shafer,et al.  Cationic Antimicrobial Peptide Resistance in Neisseria meningitidis , 2005, Journal of bacteriology.

[5]  R. Hancock,et al.  Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances , 2008, Nature Protocols.

[6]  Santiago Ramón-García,et al.  Synergistic Drug Combinations for Tuberculosis Therapy Identified by a Novel High-Throughput Screen , 2011, Antimicrobial Agents and Chemotherapy.

[7]  P. Gounon,et al.  Identification of the surface-exposed lipids on the cell envelopes of Mycobacterium tuberculosis and other mycobacterial species , 1996, Journal of bacteriology.

[8]  J. Gunn,et al.  The Salmonella PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. , 2008, Trends in microbiology.

[9]  A. Peschel,et al.  Staphylococcus aureus evasion of innate antimicrobial defense. , 2008, Future microbiology.

[10]  Yibing Huang,et al.  Alpha-helical cationic antimicrobial peptides: relationships of structure and function , 2010, Protein & Cell.

[11]  R. Hodges,et al.  Anti-tuberculosis activity of α-helical antimicrobial peptides: de novo designed L- and D-enantiomers versus L- and D-LL-37. , 2011, Protein and peptide letters.

[12]  Handbook of Anti-Tuberculosis Agents , 2008 .

[13]  D. Arad,et al.  Screening of Compounds Toxicity against Human Monocytic cell line-THP-1 by Flow Cytometry , 2004, Biological Procedures Online.

[14]  R. Hancock,et al.  Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies , 2006, Nature Biotechnology.

[15]  K. Brogden.  Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? , 2005, Nature Reviews Microbiology.

[16]  Artem Cherkasov,et al.  Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. , 2009, ACS chemical biology.

[17]  Kai Hilpert,et al.  Use of luminescent bacteria for rapid screening and characterization of short cationic antimicrobial peptides synthesized on cellulose using peptide array technology , 2007, Nature Protocols.

[18]  R. Hancock,et al.  Deciphering the Mode of Action of the Synthetic Antimicrobial Peptide Bac8c , 2011, Antimicrobial Agents and Chemotherapy.

[19]  A. Rao,et al.  In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis , 1996, Infection and immunity.

[20]  R. Hancock,et al.  Short Cationic Antimicrobial Peptides Interact with ATP , 2010, Antimicrobial Agents and Chemotherapy.

[21]  S. Lovas,et al.  The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. , 2001, Biochemistry.

[22]  Ralf Mikut,et al.  Interpretable Features for the Activity Prediction of Short Antimicrobial Peptides Using Fuzzy Logic , 2009, International Journal of Peptide Research and Therapeutics.

[23]  T. Kamradt,et al.  Cross-reactivity of T lymphocytes in infection and autoimmunity , 2004, Molecular Diversity.

[24]  F. Portaels,et al.  Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. , 2005, The Journal of antimicrobial chemotherapy.

[25]  R. Hancock,et al.  Antibacterial peptides for therapeutic use: obstacles and realistic outlook. , 2006, Current opinion in pharmacology.

[26]  Robert E W Hancock,et al.  A re-evaluation of the role of host defence peptides in mammalian immunity. , 2005, Current protein & peptide science.

[27]  H. Sahl,et al.  Antibiotic activities of host defense peptides: more to it than lipid bilayer perturbation. , 2011, Natural product reports.

[28]  S. Hoffner,et al.  In vitro activity of PR-39, a proline-arginine-rich peptide, against susceptible and multi-drug-resistant Mycobacterium tuberculosis. , 2001, The Journal of antimicrobial chemotherapy.

[29]  Søren Neve,et al.  Plectasin, a Fungal Defensin, Targets the Bacterial Cell Wall Precursor Lipid II , 2010, Science.

[30]  Ralf Mikut,et al.  Computer-based analysis, visualization, and interpretation of antimicrobial peptide activities. , 2010, Methods in molecular biology.

[31]  B. Mishra,et al.  Cathelicidin is involved in the intracellular killing of mycobacteria in macrophages , 2011, Cellular microbiology.

[32]  W. Bishai,et al.  The Two-Domain LysX Protein of Mycobacterium tuberculosis Is Required for Production of Lysinylated Phosphatidylglycerol and Resistance to Cationic Antimicrobial Peptides , 2009, PLoS pathogens.

[33]  C. Thompson,et al.  Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. , 2006, Trends in microbiology.

[34]  Shigeru Tsuchiya,et al.  Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1) , 1980, International journal of cancer.

[35]  Kai Hilpert,et al.  Peptide arrays on cellulose support: SPOT synthesis, a time and cost efficient method for synthesis of large numbers of peptides in a parallel and addressable fashion , 2007, Nature Protocols.

[36]  H. Sahl,et al.  The co-evolution of host cationic antimicrobial peptides and microbial resistance , 2006, Nature Reviews Microbiology.

[37]  C. Fjell,et al.  Identification of novel antibacterial peptides by chemoinformatics and machine learning. , 2009, Journal of medicinal chemistry.

[38]  D. Sturdevant,et al.  The antimicrobial peptide‐sensing system aps of Staphylococcus aureus , 2007, Molecular microbiology.

[39]  M. Zasloff.  Antimicrobial peptides of multicellular organisms , 2002, Nature.

[40]  Kai Hilpert,et al.  High-throughput generation of small antibacterial peptides with improved activity , 2005, Nature Biotechnology.

[41]  Gisbert Schneider,et al.  Designing antimicrobial peptides: form follows function , 2012, Nature Reviews Drug Discovery.

[42]  A. Peschel,et al.  Broad‐spectrum antimicrobial peptide resistance by MprF‐mediated aminoacylation and flipping of phospholipids , 2011, Molecular microbiology.

[43]  D. Andersson,et al.  Mechanism and Fitness Costs of PR-39 Resistance in Salmonella enterica Serovar Typhimurium LT2 , 2008, Antimicrobial Agents and Chemotherapy.